U.S. Patent No. 6,653,104 covers an anti-cancer antibody and is owned by the pharmaceutical company Immunomedics. In a seemingly unprecedented move, the U.S. Government Department of Health & Human Services (HHS) has requested an inter-partes reexamination of the issued patent.
Does Immunomedics have any case for arguing that the reexamination request should be denied and that the U.S. Government can only obtain reexamination through a Director Ordered Reexam?
Link:
- IP Law Bulletin’s Article Covering the Issue (Subscription Req’d)
- Official Gazette Notice
- Request for Reexam
HHS Requests Inter-Partes Reexamination of Immunomedics Patent
As tipped off by Dennis Crouch’s Patently Obvious blog, the U.S. Government Department of Health & Human Services (HHS) has requested an inter-partes reexamination of U.S. Pat. No. 6,653,104 for an anti-cancer antibody assigned to Immunomedics, Inc. Se…
Comments are closed.